Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
500 mg | 在庫あり | ¥ 10,000 | |||
1 g | 在庫あり | ¥ 15,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,500 |
説明 | (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats. |
In vivo | Diabetic rats were administered myrtenal (80 mg/kg bw) for a period of 28 days. Diabetic rats showed an increased the levels of plasma glucose, decreased the levels of plasma insulin, down-regulation of insulin receptor substrate 2 (IRS2), Akt and glucose transporter 2 (GLUT2) in liver and insulin receptor substrate 2 (IRS2), Akt and glucose transporter 4 (GLUT4) protein expression in skeletal muscle[1]. |
別名 | (1R)-(−)-Myrtenal |
分子量 | 150.22 |
分子式 | C10H14O |
CAS No. | 18486-69-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (199.71 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(−)-Myrtenal 18486-69-6 Others Akt hyperglycemia terpene inhibit GLUT2 Protein kinase B Inhibitor diabetic (1R)-(−)-Myrtenal (−) Myrtenal (?)-Myrtenal PKB (−)Myrtenal inhibitor